COMP <GO>
INSM vs LLY // EV/EBITDA & P/E VALUATION
Insmed Incorporated (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: INSM 3
— LLY 11
■ METRIC PARITY
LAST: $112.58 (+0.89%) • MKT CAP: $24.37B
valuation
—
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
valuation
36.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INSM VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INSM | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 79.70% | 83.64% | -3.94 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 32.36% | -67.36 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.97% | 2.30% | -6.27 | LLY | /fcf-yield <GO> |
| Operating Margin | -60.00% | 40.21% | -100.21 | LLY | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 31.90% | -91.90 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 66.70% | 45.51% | +21.19 | INSM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.25 | 9.29 | -4.04 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 9/9 | -4.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.00% | 6.77% | +0.23 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 62.7 | 77.9 | -15.15 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.03 | 0.51 | +0.52 | INSM | /macro-sensitivity <GO> |
| Forward P/E Multiple | 21.0x | 26.3x | -5.25 | INSM | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $24.37B | $1.33T | -$1.31T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INSM REV | LLY REV | INSM GROSS % | LLY GROSS % | INSM FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $606.4M | $65.18B | 79.7% | 83.0% | -$967.6M | $16.81B |
| FY 2024 | $363.7M | $45.04B | 76.4% | 81.3% | -$705.8M | $8.82B |
| FY 2023 | $305.2M | $34.12B | 44.0% | 79.3% | -$550.0M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INSM // BETA 1.03
LLY // BETA 0.51